Based on the findings from this study, reduction, not ablation, of Rap1a could be a potential therapeutic target to reduce the level of AGE/RAGE signaling in diabetic conditions, and possibly reduce the risk for developing cardiovascular disease. This evidence concerns the gene RAP1A and cardiovascular disorder.